MA55089A - Traitements combinés et stratification des patients avec des anticorps bispécifiques anti-egfr/c-met - Google Patents

Traitements combinés et stratification des patients avec des anticorps bispécifiques anti-egfr/c-met

Info

Publication number
MA55089A
MA55089A MA055089A MA55089A MA55089A MA 55089 A MA55089 A MA 55089A MA 055089 A MA055089 A MA 055089A MA 55089 A MA55089 A MA 55089A MA 55089 A MA55089 A MA 55089A
Authority
MA
Morocco
Prior art keywords
egfr
bispecific antibodies
combination treatments
patient stratification
met bispecific
Prior art date
Application number
MA055089A
Other languages
English (en)
Inventor
Sheri Moores
Smruthi Vijayaraghavan
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MA55089A publication Critical patent/MA55089A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
MA055089A 2019-02-26 2020-02-24 Traitements combinés et stratification des patients avec des anticorps bispécifiques anti-egfr/c-met MA55089A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962810716P 2019-02-26 2019-02-26
US201962930190P 2019-11-04 2019-11-04

Publications (1)

Publication Number Publication Date
MA55089A true MA55089A (fr) 2022-01-05

Family

ID=72142314

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055089A MA55089A (fr) 2019-02-26 2020-02-24 Traitements combinés et stratification des patients avec des anticorps bispécifiques anti-egfr/c-met

Country Status (14)

Country Link
US (2) US11459391B2 (fr)
EP (1) EP3931224A4 (fr)
JP (1) JP2022521610A (fr)
KR (1) KR20210132117A (fr)
CN (1) CN113840842A (fr)
AU (1) AU2020229467A1 (fr)
BR (1) BR112021016149A2 (fr)
CA (1) CA3131654A1 (fr)
IL (1) IL285718A (fr)
JO (1) JOP20210233A1 (fr)
MA (1) MA55089A (fr)
MX (1) MX2021010265A (fr)
SG (1) SG11202108311RA (fr)
WO (1) WO2020174370A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11879013B2 (en) * 2019-05-14 2024-01-23 Janssen Biotech, Inc. Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
US11850248B2 (en) * 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
EP4304644A1 (fr) * 2021-03-09 2024-01-17 Janssen Biotech, Inc. Traitement de cancers dépourvus de mutations activant l'egfr
CA3227802A1 (fr) * 2021-07-29 2023-02-02 Board Of Regents, The University Of Texas System Procedes et compositions pour le traitement du cancer mutant kras
KR20230049243A (ko) 2021-10-06 2023-04-13 주식회사 엘지에너지솔루션 태양광 시스템과 연계하는 에너지 저장 시스템 및 에너지 저장 시스템의 제어 방법
US20230183360A1 (en) * 2021-12-09 2023-06-15 Janssen Biotech, Inc. Use of Amivantamab to Treat Colorectal Cancer

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0672142B1 (fr) 1992-12-04 2001-02-28 Medical Research Council Proteines de liaison multivalentes et multispecifiques, leur fabrication et leur utilisation
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
EP2354149B1 (fr) 2000-12-12 2017-08-30 MedImmune, LLC Molécules à demi-vies longues, compositions et utilisations de celles-ci
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
EP3611273A1 (fr) 2004-03-31 2020-02-19 The General Hospital Corporation Procédé pour déterminer la réactivité du cancer aux traitements de ciblage de récepteur de facteur de croissance épidermique
JP2008504809A (ja) 2004-06-04 2008-02-21 ジェネンテック・インコーポレーテッド Ｅｇｆｒ突然変異
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
CN101141981A (zh) 2005-01-21 2008-03-12 健泰科生物技术公司 Her抗体的固定剂量给药
CN101193905B (zh) 2005-02-11 2014-06-25 纪念斯隆-凯特林癌症中心 用于检测抗药egfr突变体的方法和组合物
WO2006091899A2 (fr) 2005-02-24 2006-08-31 Amgen Inc. Mutations de recepteur de facteur de croissance epidermique
ES2539790T3 (es) 2005-03-25 2015-07-06 Genentech, Inc. Métodos y composiciones para modular c-met hiperestabilizado
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
PL1999154T3 (pl) 2006-03-24 2013-03-29 Merck Patent Gmbh Skonstruowane metodami inżynierii heterodimeryczne domeny białkowe
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CA2683559C (fr) 2007-04-13 2019-09-24 Dana Farber Cancer Institute, Inc. Methodes de traitement d'un cancer resistant a des agents therapeutiques anti-erbb
EP2069401A4 (fr) 2007-07-31 2011-02-23 Medimmune Llc Protéines de liaison à épitope multispécifiques et leurs utilisations
US7892770B2 (en) 2007-08-24 2011-02-22 Van Andel Research Institute Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods
ES2564523T3 (es) 2007-12-19 2016-03-23 Janssen Biotech, Inc. Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
TW200942552A (en) * 2008-03-06 2009-10-16 Genentech Inc Combination therapy with c-Met and HER antagonists
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
EA201201435A1 (ru) 2010-04-20 2013-04-30 Генмаб А/С ГЕТЕРОДИМЕРНЫЕ АНТИТЕЛО-Fc-СОДЕРЖАЩИЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
US8962808B2 (en) 2010-05-05 2015-02-24 The Research Foundation For The State University Of New York EGFR-related polypeptides and methods of use
MX352929B (es) 2010-11-05 2017-12-13 Zymeworks Inc DISEÑO DE ANTICUERPOS HETERODIMÉRICOS ESTABLES CON MUTACIONES EN EL DOMINIO Fc.
CA2825255C (fr) 2011-01-24 2021-05-18 Ym Biosciences Inc. Anticorps selectifs des cellules presentatrices des recepteurs de egf a haute densite
EP2688909A2 (fr) 2011-03-25 2014-01-29 Glenmark Pharmaceuticals S.A. Immunoglobulines hétéro-dimériques
KR20130036993A (ko) 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
CN107266577B (zh) 2011-10-11 2022-09-13 弗·哈夫曼-拉罗切有限公司 双特异性抗体的改进的组装
DK2773671T3 (da) 2011-11-04 2021-11-15 Zymeworks Inc Udformning af stabilt heterodimert antistof med mutationer i fc-domænet
SI2922872T1 (sl) 2012-11-21 2019-01-31 Janssen Biotech, Inc., Bispecifična protitelesa EGFR/C-MET
US20170275367A1 (en) * 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
WO2015043614A1 (fr) 2013-09-26 2015-04-02 Biontech Ag Procédés et compositions pour prédire une efficacité thérapeutique de traitements de cancer et de pronostic de cancer
US10081680B2 (en) * 2014-03-11 2018-09-25 The Board Of Trustees Of The Leland Stanford Junior University Anti-SIRP-alpha antibodies and bispecific macrophage enhancing antibodies
CN106660993B (zh) 2014-06-12 2020-09-11 上海复尚慧创医药研究有限公司 一类激酶抑制剂
PL3604294T3 (pl) 2014-10-13 2021-11-02 Yuhan Corporation Związki i kompozycje do modulowania aktywności zmutowanych kinaz EGFR
SG11201704058TA (en) 2014-11-18 2017-06-29 Janssen Pharmaceutica Nv Cd47 antibodies, methods, and uses
CN107427515B (zh) * 2014-12-03 2021-11-16 奥克兰联合服务有限公司 用于治疗癌症的激酶抑制剂前药
US20160333087A1 (en) * 2015-05-12 2016-11-17 Bioven 3 Limited Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors
LT3365373T (lt) 2015-10-23 2021-05-25 Merus N.V. Surišančios molekulės, kurios inhibuoja vėžio augimą
EP3383435A4 (fr) 2015-11-30 2019-07-10 Medimmune, LLC Rapports optimisés d'acides aminés et de sucres en tant que composés stabilisants amorphes dans des compositions pharmaceutiques contenant des concentrations élevées d'agents thérapeutiques à base de protéine
WO2017200016A1 (fr) 2016-05-17 2017-11-23 公益財団法人がん研究会 Agent thérapeutique pour le cancer bronchique ayant acquis une résistance à egfr-tki
CN109415441B (zh) 2016-05-24 2023-04-07 英斯梅德股份有限公司 抗体及其制备方法
GB201611123D0 (en) 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
IL265362B1 (en) 2016-09-14 2024-01-01 Merck Patent Gmbh Antibodies against C-MET and drug conjugates containing such antibodies
WO2018094225A1 (fr) 2016-11-17 2018-05-24 Board Of Regents, The University Of Texas System Composés à activité antitumorale contre des cellules cancéreuses porteuses de mutations egfr ou her2 exon 20
EP3585814A4 (fr) 2017-02-22 2021-04-14 University of Saskatchewan Agents de liaison à l'egfr et leurs utilisations
AR111469A1 (es) 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
KR20210066819A (ko) 2018-09-04 2021-06-07 레인 세러퓨틱스 인코포레이티드 Her-유도 암을 치료 또는 예방하기 위한 화합물, 조성물 및 방법
EP3946293A4 (fr) 2019-03-29 2023-05-03 Board of Regents, The University of Texas System Composés à activité antitumorale contre des cellules cancéreuses portant des insertions d'exon 20 d'egfr ou de her2
EP3956035A4 (fr) 2019-04-17 2023-01-25 Board of Regents, The University of Texas System Composés contre le cancer portant des mutations egfr résistantes aux inhibiteurs de la tyrosine kinase
CA3132816A1 (fr) 2019-04-17 2020-10-22 Board Of Regents, The University Of Texas System Composes ayant une activite antitumorale contre des cellules cancereuses portant des mutations egfr resistantes aux inhibiteurs de tyrosine kinase
US11879013B2 (en) 2019-05-14 2024-01-23 Janssen Biotech, Inc. Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors

Also Published As

Publication number Publication date
IL285718A (en) 2021-10-31
WO2020174370A3 (fr) 2020-12-03
AU2020229467A1 (en) 2021-08-12
CN113840842A (zh) 2021-12-24
US20200270351A1 (en) 2020-08-27
BR112021016149A2 (pt) 2021-10-13
US11459391B2 (en) 2022-10-04
JOP20210233A1 (ar) 2023-01-30
WO2020174370A2 (fr) 2020-09-03
SG11202108311RA (en) 2021-09-29
EP3931224A2 (fr) 2022-01-05
CA3131654A1 (fr) 2020-09-03
MX2021010265A (es) 2021-09-23
KR20210132117A (ko) 2021-11-03
US20230130600A1 (en) 2023-04-27
JP2022521610A (ja) 2022-04-11
EP3931224A4 (fr) 2023-03-01

Similar Documents

Publication Publication Date Title
MA55089A (fr) Traitements combinés et stratification des patients avec des anticorps bispécifiques anti-egfr/c-met
FR23C1010I2 (fr) Anticorps bispecifiques anti-ang-2/anti-vegf et leur utilisation dans le traitement des maladies vasculaires oculaires
CL2018002138A1 (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, subaguda o crónica.(divisional solicitud 201600400)
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
PH12016501728A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
PH12014501685A1 (en) Humanized antibodies that recognize alpha-synuclein
EA201500934A1 (ru) Кардио- и нефропротективная противодиабетическая терапия
EA201690212A1 (ru) Способы лечения или профилактики офтальмологических патологических состояний
EA201791199A1 (ru) Способ лечения болезни альцгеймера
EA201500364A1 (ru) Лечение глазных заболеваний
MA46621A (fr) Traitements combinés comprenant l'administration d'imidazopyrazinones
EA201792447A1 (ru) Способы и композиции для диагностики и лечения заболеваний у пациентов, имеющих повышенные уровни cxcl9 и других биомаркеров
WO2012145535A3 (fr) Modèle animal de cancer humain et procédés pour son utilisation
IL276896A (en) Methods for treating Crohn's disease with a specific anti-IL23 antibody
SI3749308T1 (sl) Zdravljenje bolnikov s klasično Fabryjevo boleznijo z migalastatom
EA201500363A1 (ru) Человеческие анти-vegfr-2/kdr-антитела
JP2021504412A5 (fr)
PL3806895T3 (pl) Przeciwciała, które wiążą się z tkanką nowotworową i ich zastosowania diagnostyczne i terapeutyczne
ECSP17019893A (es) Tratamientos médicos a base de anamorelina
EA201500765A1 (ru) Способы лечения сердечно-сосудистых заболеваний
CY1120727T1 (el) Συνδυασμοι με ενα πεπτιδιο κυκλοποιημενου σκελετου
CY1119308T1 (el) Συνδυασμοι με ενα πεπτιδιο κυκλοποιημενου σκελετου
EA201500232A1 (ru) Три(гетеро)арилпиразолы и их применение
EA201890014A1 (ru) Терапевтические композиции, содержащие дипиридамол, наборы для лечения, содержащие эти композиции, и способы их производства